Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Trending in China: Should Internet Celebrities Be Part of the School Curriculum?
Sequoia China Leads Nearly $100m Round in Storytelling App Kuaidian
Medical Robot Maker Finds Elixir in STAR Board’s Market Reforms
Trending in China: Outrage Ensues as Updated U.S. Student Visa Policies Force International Students into a Dilemma
Tencent’s PUBG Mobile Game Hits $3 Billion Milestone
Luckin Coffee Shareholders Vote to Remove Chairman, Bloomberg Reports
France Won’t Ban But Will Discourage Use of Huawei 5G Equipment, Official Says
Trending in China: ‘Lipstick King’ Li Jiaqi Settles in Shanghai, Prompting a Rethink of ‘Talent’
Tencent Plays in U.S. With California Game Studio Launch
Trending in China: Shenzhen Thinks Only Children Should Get Paid Leave to Look After Their Parents - Cue Heated Debate
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise
Chinese Self-Driving Truck Firm Aims to Cover Most of U.S. by 2024
Trending in China: Chinese Netizens Tell Indian Prime Minister Modi To ‘Shut The Door On The Way Out’ As He Quits Weibo
Trending in China: If You Can’t Beat Them, Join Them – Why Tencent is Laughing At Itself
Meituan Eyes Robot-Enabled Deliveries with $14 Million Investment in PuduTech
India Ban Could Hit TikTok’s Parent Company to the Tune of $6 Billion
Sina Weibo to Issue $750 Million in Bonds
Embattled Leshi Forced to Sell Smart TV, Livestreaming Trademarks
Autowise.ai and Swiss Cleaning Carmaker Launch Driverless Street Sweeper
Trending in China: How an ‘Old Godmother’ Took on China’s Internet Giant and Won
Dr Reddy’s Is First Indian Drugmaker Accepted by China Pilot Program

By Di Ning, Liu Denghui, Liang Zhen and Han Wei / Sep 25, 2019 05:08 AM / Business & Tech

Photo: VCG

Photo: VCG

Dr Reddy's Laboratories Ltd. became the first Indian pharmaceutical company to win approval to supply certain generic drugs to China’s biggest public hospitals as the country expands a drug procurement pilot program nationwide.

The Indian drugmaker was among three winners, including two domestic companies, to supply Olanzapine, an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder, according to bidding results released Tuesday.

Dr Reddy’s Olanzapine passed state review in September for eligibility to participate in the procurement bidding. The company offered a 35% price cut to win the bidding and will supply the drug to public hospitals in several provinces including Zhejiang, Hunan and Guangxi.

China expanded a drug procurement pilot program nationwide Tuesday to reduce the cost of generic medicines. The trial, announced in December, originally involved 11 major cities, including Beijing, Shanghai and Guangzhou, where drugmakers were asked to submit bids to supply 25 commonly used generic drugs to hospitals.

A total of 77 pharmaceutical companies participated in the latest round of bidding, and 45 of them were accepted. The average price of winning bids is 25% lower than prices set during last year’s pilot program, according to a statement issued by the office overseeing the test. Last year’s trial pared the prices of the same drugs by an average of 52%, according to Bloomberg.

Global drugmakers have been adjusting their China strategies as the new procurement plan will erode the once-high margins on off-patent drugs.

Related: China Reshuffles Medical Reimbursement List, Adding New Drugs


Share this article
Open WeChat and scan the QR code